Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously e...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Thiago S. Lima, Luciano O. Souza, Diego Iglesias-Gato, Johanna Elversang, Flemming Steen Jørgensen, Tuula Kallunki, Martin A. Røder, Klaus Brasso, José M.A. Moreira
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2022-06-01
Seria:	Frontiers in Pharmacology
Hasła przedmiotowe:	metastatic castration-resistant prostate cancer docetaxel resistance cellular models androgen independence drug repurposing
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fphar.2022.869461/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!